Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you Doc Logic for scrutinizing the report and isolating items of interest for NWBO supporters on this board. The link in my post brought interested parties to TrakCel, a COP (cell orchestration platform) company mentioned in a previous post.
Your expertise and attentiveness to small details, often times hidden, are impressive.
“The medical community and patients are becoming aware of the efficacy of cell therapy.”
Sorry for your sadness, Eagle. My deepest sympathies.
Know when to “fold them”
White flag
Checkmate
Most of us are aware that LP is on the agenda to speak at the Cancer Vaccines Conference in London on September 27th. In reviewing the conference’s website, I was curious as to some of the verbiage in the “overview” of the conference on the site - the last sentence in the quoted paragraph that follows:
“With focal points of the conference including autologous tumour cell immunotherapy, combinatorial approaches (including immune checkpoint inhibitors and IDO inhibitors) and case studies of current clinical trials, this conference will provide the perfect platform to highlight emerging strategies in cancer vaccines. The conference will also aim to provide solutions to circumvent the challenges which face the development of successful targeted cancer treatments, within a competitive and important market.”
https://www.smi-online.co.uk/pharmaceuticals/uk/cancer-vaccines?utm_medium=www.cancervaccinesevent.com&utm_source=P-221&utm_campaign=ihub#tab_overview
Also noted: NWBO is the only sponsor for this conference.
“If (as many here claim) NWBO is doing exactly what AZN did, why not do it right? Why not redesign the trial and re-allocate the alpha? Why the secrecy?”
Your post duly noted:
AZN is a powerful brand; they have earned their status and respect, they can approach and address issues with credibility and confidence - not so with NWBO, the possible disruptor in an arena of giants. NWBO enjoys no such recognition. Their corporate behavior parallels the reality of their position at this time. As we are all witnessing, their strategy seems to be “keep your heads low and fly under the radar” until………
IMO of course.
Hey, Good Morning Eagle
Well, let’s see what this interesting day brings to the table.
AZN’s Mystic fails PFS
https://www.firstwordpharma.com/node/1491563?tsid=28
Thank you Doc Logic
As expected from you, a precise, factual, and succinct post.
Possibly you’re referring to a complaint filed in the U.K. in June 2015. I believe that NWBO placed a piece about the availability of a DCVax clinical trial. My guess is that the “complaint” didn’t come from any cancer victim nor their family.
https://www.gov.uk/government/publications/advertising-investigations-august-2015/24-august-2015-advertising-an-unlicensed-medicine#contents
Unfortunately, I don't have the publication piece.
I think you missed the point!
The response is to CherryTree1’s:
“It is really strange. It is like some really powerful forces are putting a lid on DCVAX. I really wonder if John McCain will be told the truth about DCVAX.”
There is no question as to Mr. Black’s confidence in NWBO.
Maybe some enlightenment from Cofer Black would clarify DCVax’s lack of recognition and respect in certain realms.
“3 institutions are taking 7 figure positions in NWBO starting this week and thats a fact. “
Are you sure they're not wearing “Bully Boots?”
“It is a pay-to-play deal. Linda has used this for selling stock for years. “
I’m not quite understanding your post. In the trade show/conference business, sponsorship packages are offered to those attendees who wish to highlight their visibility at a higher level and take the packages’ additional opportunities to market to a targeted audience.
Also note that Northwest Biotherapeutics is Gold Sponsor of this conference
https://www.smi-online.co.uk/pharmaceuticals/uk/cancer-vaccines?utm_medium=www.cancervaccinesevent.com&utm_source=P-221&utm_campaign=ihub#tab_sponsors
NWDR
Despite the differences we express on this MB, I’m certain we are all together in offering you and your wife good wishes and our heartfelt prayers.
For what its worth, I seem to remember that Dr. Bosch mentioned the Sarcoma Oncology Center (Dr. Chawla) when referencing the upcoming trial.
https://sarcomaoncology.com
http://grammarist.com/idiom/go-big-or-go-home/
Go big or go home
Go big or go home is an American idiom that has a fairly recent origin. We will look at the definition of the phrase go big or go home, the surprising origin of the phrase and some examples of its use in sentences.
Go big or go home is an exhortation to go all-out, to put all of one’s effort into an enterprise, to experience something to its fullest, to be extravagant. Go big or go home is a philosophy that encourages one to be bold. The phrase is said to have originated as a sales slogan in the 1990s. A motorcycle parts company in Southern California incorporated the term go big or go home in its packaging for some oversized Harley Davidson pipes. However, there are some who say that the term was derived from the jargon of the sport of mogul skiing in the 1980s. According to this origin story, skiers taunted each other into more and more spectacular skiing runs with the terms go hard or go home and go big or go home. Others believe that go big or go home originated in the sport of surfing. In any case, it is probably safe to assume that the idiom go big or go home came out of Southern California in the latter part of the twentieth century. The idiom is hyphenated when used as an adjective before a noun, as in go-big-or-go-home.
Why crow before the sunrise?
I believe this was SOS last comment
https://smithonstocks.com/northwest-biotheraputics-to-make-presentation-at-asco-today-monday-june-5-2017/
Take care
We have a Winner!
As I was sitting here reading IHub posts, with drink in hand I might add, my eyes wandered to the NWBO chart on the right hand side of the screen. How glaringly obvious is that graph?
When they say, “A picture is worth a thousand words,” this one surely is that.
Good thoughts and prayers are with you.
Coincidentally, NW’s new fund - Income Focus Fund - has Astra Zeneca topping that portfolio at 7.39% as of 30 April 2017.
Just saying!
A beautiful thought reg2015
“Our prime purpose in this life is to help others. And if you can't help them, at least don't hurt them.”
Dalai Lama
HL….
“If HE and EAMS are any guide the validation is mostly talk, and little action” ….Happy Librarian
Perhaps the following can be considered: Cognate is one of six (6) integration partners with TrakCel and TrakCel’s home page, regarding their cell orchestration platform, states:
“Regulatory compliance and validation
Designed to meet FDA, EMA and PIC/S validation requirements”
https://trakcel.com
I believe Catapult UK is also collaborating with TrakCel. TrakCel just announced two additional companies collaborating with them - SavSu of Albuquerque NM (cold chain technology/shipping containers was one of them.
TrakCel, Cardiff, Wales, and Cognate BioServices.
I have been following TrakCel’s buildup of their cellular orchestration delivery technologies and their partnership with Cognate BioServices along with other integration partners. This company is developing an infrastructure for commercialization of cell therapies.
I came across TrakCel when noting Robert Margolin (former VP of Corporate Development, Cognate) was recently named VP of Corporate Development and Strategy at TrakCel.
Interesting information from TrakCel’s website: a number of TrakCel's BOD seats are held by Telegraph Hill Partners, a venture capital firm focusing on the life science industry. THP announced in October of last year, a multi-million dollar investment in TrakCel.
For those interested:
https://trakcel.com/index.html
https://thpartners.net
Ah yes, Andy Card; and, he was on Squawk Box this morning
Yes, I know you are aware - it was just a reminder as to the importance of the partnerships, collaborations and ecosystems building within this industry. Biotech news is coming in by the shipload!
Mr. Black made this statement during an interview when assuming a BOD seat with Burisma:
“When I advise companies on strategic development, economic factors play a major role as well as political and financial risk.”
http://ukraine.financialsweb.com/economy/joseph-cofer-black-ldquoi-am-excited-to-join-burisma039s-board-of-directors-and-to-focus-on-strategic-development-and----kyiv-post.html
Asterias Agreement with Cognate BioServices
AST-VAC1 (antigen-presenting autologous dendritic cells
• In August 2016, Asterias entered into a Development and Manufacturing Services Agreement with Cognate BioServices, Inc., a third party providing process development and cGMP manufacturing services, to perform process development studies in support of Asterias’ clinical and commercial development of AST-VAC1 and production and manufacturing of AST-VAC1 under cGMP. In parallel with ongoing process development efforts, the company is currently developing plans for further progressing the AST-VAC1 clinical program.
http://asteriasbiotherapeutics.com/inv_news_listings.php?listing=1383
Do you have another shtick you can put forth; this performance is getting old.
NWBO is a player and possibly a leader in the IO field.
“Biologic medicines are revolutionizing the treatment of cancer and autoimmune disorders and are critical to the future of the industry.”
US Dept of Commerce
https://www.selectusa.gov/pharmaceutical-and-biotech-industries-united-states
Thank you BSB
A great synopsis of the IO trial landscape.
FDA in Center of Debate over Developing, Pricing New Cancer Therapies
http://www.pharmexec.com/fda-center-debate-over-developing-pricing-new-cancer-therapies
Apologies if this article was previously posted.
Sorry, Captain, for your sadness